Bergenin can regulate the excretion of serum uric acid in the body by regulating the expression levels of ATP-binding cassette subfamily G member 2(ABCG2) and GLUT9, and at the same time, it can reduce the inflammatory response in the body, so it has high potential in the treatment of hyperuricemia and its complications (51). This evidence concerns the gene SLC2A9 and hyperuricemia.